Low-Dose Opioid Combination Therapy for Pain Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid medications, despite their analgesic effectiveness, pose challenges due to the risk of tolerance development, physical dependence, and psychological dependence, leading to limitations in their use for pain management, particularly as evidenced by the opioid epidemic, where patients often suffer from chronic pain due to restrictive CDC guidelines on morphine milligram equivalents (MME).
Innovation Solution
Development of pharmaceutical compositions combining codeine or its salts with hydroxyzine, gabapentinoids, and 5-HT3 antagonists, along with excipients, to provide effective pain relief while maintaining MME levels below 90, thereby reducing the risk of adverse effects such as dysphoria and withdrawal symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high MME opioid doses are prescribed to achieve adequate pain relief, then pain relief effectiveness is improved, but the risk of tolerance, physical dependence, and psychological dependence increases
Solution Approach 1:
The patent combines multiple active ingredients (opioid agonist, hydroxyzine, gabapentinoid, and optionally 5-HT3 antagonist) into a single pharmaceutical composition. This synergistic combination allows the opioid component to be used at lower MME doses (below 90) while maintaining effective pain relief through the additive and synergistic effects of the other ingredients, thereby reducing the risk of tolerance and dependence associated with high-dose opioid monotherapy.
Solution Approach 2:
The invention creates a composite pharmaceutical formulation integrating four distinct therapeutic agents with different mechanisms of action. The opioid agonist provides analgesia, hydroxyzine contributes anxiolytic and sedative effects, gabapentinoid addresses neuropathic pain components, and the 5-HT3 antagonist prevents nausea. This composite approach achieves comprehensive pain management at lower opioid doses, mitigating the harmful effects of high MME regimens.
2Object-affected harmful factors
If CDC MME limits are enforced to reduce opioid epidemic risks, then the complication rate is reduced, but many patients are left to suffer from pain due to inadequate relief
Solution Approach 1:
The patent merges multiple pain management mechanisms into one formulation, enabling compliance with CDC MME<90 guidelines while delivering adequate pain relief. The combination of opioid agonist (at low MME), hydroxyzine (for anxiety and sedation), gabapentinoid (for neuropathic pain), and 5-HT3 antagonist (for nausea prevention) creates a multi-modal analgesic effect that satisfies both regulatory requirements and clinical needs.
Solution Approach 2:
The invention changes the therapeutic parameters by shifting from high-dose opioid monotherapy to low-dose opioid combination therapy. By adjusting the dosage regimen to MME<90 and supplementing with non-opioid agents, the formulation maintains analgesic effectiveness while reducing opioid-related complications, thereby aligning with CDC guidelines without compromising patient comfort.
3Reliability
If traditional opioid regimens are used to treat chronic pain, then significant pain relief is achieved, but dysphoria and withdrawal symptoms increase
Solution Approach 1:
The patent converts the harmful side effects of traditional opioid therapy into beneficial outcomes by incorporating antagonistic and modulating agents. Hydroxyzine counteracts opioid-induced dysphoria through its antihistaminic and anxiolytic properties, while the gabapentinoid and 5-HT3 antagonist further mitigate withdrawal symptoms and enhance overall tolerability. This transforms the harmful profile of high MME regimens into a beneficial, well-tolerated treatment option.
Data Source
AI summary
Disclosed herein, in part, are pharmaceutical compositions comprising an opioid agonist such as codeine or a pharmaceutically acceptable salt thereof, hydroxyzine or a pharmaceutically acceptable salt thereof, a gabapentinoid, optionally a 5-HT3 antagonist and a pharmaceutically acceptable excipient. Methods of treating neuropathic and nociceptive pain comprising administering a disclosed pharmaceutical composition to a subject in need thereof is also provided herein